Evidence map›Paper›PMID 33082228›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases.

Meng Wu, Yaobing Chen, Han Xia, Changli Wang, Chin Yee Tan, Xunhui Cai, Yufeng Liu, Fenghu Ji, Peng Xiong, Ran Liu and 16 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 1 synthesis or guideline pooled it, 210 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. TheBiomolecules · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Review
  19. Review
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 2 countries.

Meng WuDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.
Yaobing ChenInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Han XiaDepartment of Research and Development, Hugobiotech Co., Ltd., 100000 Beijing, P. R. China.ORCID 0000-0002-5179-0255
Changli WangDepartment of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Chin Yee TanDepartment of Pediatrics, Duke University School of Medicine, Durham, NC 27710.ORCID 0000-0003-1104-6082
Xunhui CaiInstitute of Artificial Intelligence, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Yufeng LiuInstitute of Artificial Intelligence, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Fenghu JiInstitute of Artificial Intelligence, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Peng XiongInstitute of Artificial Intelligence, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.ORCID 0000-0002-4606-4312
Ran LiuDepartment of Research and Development, Hugobiotech Co., Ltd., 100000 Beijing, P. R. China.ORCID 0000-0001-9146-8562
Yuanlin GuanDepartment of Research and Development, Hugobiotech Co., Ltd., 100000 Beijing, P. R. China.
Yaqi DuanInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Dong KuangInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Sanpeng XuInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Hanghang CaiInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Qin XiaDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China.
Dehua YangThe National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, P. R. China.ORCID 0000-0003-3028-3243
Ming-Wei WangThe National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, P. R. China.
Isaac M ChiuDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-0723-4841
Chao ChengDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030.
Philip P AhernDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195.ORCID 0000-0002-2083-3224
Liang LiuDepartment of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China; liuliang@mail.tjmu.du.cn wanggp@hust.edu.cn neil.surana@duke.edu tianxia@hust.edu.cn dennis_kasper@hms.harvard.edu.
Guoping WangInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China; liuliang@mail.tjmu.du.cn wanggp@hust.edu.cn neil.surana@duke.edu tianxia@hust.edu.cn dennis_kasper@hms.harvard.edu.
Neeraj K SuranaDepartment of Pediatrics, Duke University School of Medicine, Durham, NC 27710; liuliang@mail.tjmu.du.cn wanggp@hust.edu.cn neil.surana@duke.edu tianxia@hust.edu.cn dennis_kasper@hms.harvard.edu.ORCID 0000-0002-9544-2551
Tian XiaInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China; liuliang@mail.tjmu.du.cn wanggp@hust.edu.cn neil.surana@duke.edu tianxia@hust.edu.cn dennis_kasper@hms.harvard.edu.
Dennis L KasperDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115 liuliang@mail.tjmu.du.cn wanggp@hust.edu.cn neil.surana@duke.edu tianxia@hust.edu.cn dennis_kasper@hms.harvard.edu.ORCID 0000-0001-8808-5333
Tongji Hospital · CNHuazhong University of Science and Technology · CNHarvard University · USChinese Academy of Sciences · CNDuke University · USBaylor College of Medicine · USCleveland Clinic Lerner College of Medicine · USUnion Hospital · CNXi'an Jiaotong University · CN

Funding

Elucidating the Structural Requirements for Next-Gen Glycoconjugate VaccinesR01AI148273 · NIAID · HARVARD MEDICAL SCHOOL · PI KASPER, DENNIS L. · 2020 to 2024
$3.0M
NIAID NIH HHS R01 AI148273
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), the global pandemic caused by SARS-CoV-2, has resulted thus far in greater than 933,000 deaths worldwide; yet disease pathogenesis remains unclear. Clinical and immunological features of patients with COVID-19 have highlighted a potential role for changes in immune activity in regulating disease severity. However, little is known about the responses in human lung tissue, the primary site of infection. Here we show that pathways related to neutrophil activation and pulmonary fibrosis are among the major up-regulated transcriptional signatures in lung tissue obtained from patients who died of COVID-19 in Wuhan, China. Strikingly, the viral burden was low in all samples, which suggests that the patient deaths may be related to the host response rather than an active fulminant infection. Examination of the colonic transcriptome of these patients suggested that SARS-CoV-2 impacted host responses even at a site with no obvious pathogenesis. Further proteomics analysis validated our transcriptome findings and identified several key proteins, such as the SARS-CoV-2 entry-associated protease cathepsins B and L and the inflammatory response modulator S100A8/A9, that are highly expressed in fatal cases, revealing potential drug targets for COVID-19.

Indexed as

TranscriptomeAgedAged, 80 and overColonCOVID-19Fatal OutcomeFemaleHumansLungMaleMiddle AgedNeutrophil ActivationProteomeSARS-CoV-2Viral LoadProteomeCOVID-19fibrosisNETosisneutrophilSARS-CoV-2

Identifiers

PMID33082228
PMCPMC7668053
OpenAlexW3094015473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.